发明申请
- 专利标题： MODIFIED EXENDINS AND USES THEREOF
- 专利标题（中）： 修改的附件及其用途
-
申请号： US13334912申请日： 2011-12-22
-
公开(公告)号： US20120196802A1公开(公告)日： 2012-08-02
- 发明人: Aifeng LV , Changan Sun , Yali Wang
- 申请人： Aifeng LV , Changan Sun , Yali Wang
- 申请人地址： CN Jiangsu
- 专利权人： WUXI GRANDCHAMP PHARMACEUTICAL TECHNOLOGY CO., LTD.
- 当前专利权人： WUXI GRANDCHAMP PHARMACEUTICAL TECHNOLOGY CO., LTD.
- 当前专利权人地址： CN Jiangsu
- 优先权： CN200510038102.3 20050114
- 主分类号： A61K38/26
- IPC分类号： A61K38/26 ; A61P3/10 ; C07K14/605
摘要：
The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
公开/授权文献
- US08716221B2 Modified exendins and uses thereof 公开/授权日：2014-05-06